Pharmaceutical - AstraZeneca

Filter

Current filters:

AstraZeneca

Popular Filters

226 to 250 of 319 results

AstraZeneca to invest $1.2 billion in Russia by 2017; Pharmstandard deal with AVVA

28-12-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) plans to invest up to $1.2 billion in its development…

AstraZenecaAVVA PharmaceuticalsEuropeFinancialMarkets & MarketingPharmaceuticalPharmstandardProduction

AstraZeneca presents mixed data on fostamatinib in RA

13-12-2012

Shares of Anglo-Swedish drug major AstraZeneca (LSE: AZN) fell 2.1% to $47.88 in premarket US trading…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyfostamatinibPharmaceuticalResearchRigel Pharmaceuticals

EU Court of Justice dismisses AstraZeneca appeal on patent settlement

07-12-2012

The European Union's highest court, the Court of Justice, yesterday dismissed the appeal of Anglo-Swedish…

AstraZenecaEuropeGastro-intestinalsLegalLosecPatentsPharmaceutical

News briefs from Bayer, AstraZeneca and Valeant/Galderma

06-12-2012

German drug major Bayer (BAYN: DE) and partner Regeneron (Nasdaq: REGN) submitted a marketing application…

AstraZenecaBayerEuropeEyleaFaslodexGaldermaLicensingNorth AmericaOncologyOphthalmicsPerlanePharmaceuticalRegulationRestylaneValeant Pharmaceuticals

AstraZeneca inks deal for Optimer's fidaxomicin in Latin America

04-12-2012

USA-based Optimer Pharmaceuticals (Nasdaq: OPTR) says it has executed an exclusive agreement with Anglo-Swedish…

Antibiotics and Infectious diseasesAstraZenecafidaxomicinLicensingOptimer PharmaceuticalsPharmaceuticalSouth America

FDA approves Exelixis' Cometriq for rare thyroid cancer, as EMA accepts filing

30-11-2012

There were two items of good news yesterday for US drug developer Exelixis' (Nasdaq: EXEL), the first…

AstraZenecaBiotechnologycabozantinibCaprelsaCometriqEuropeExelixisNorth AmericaOncologyPharmaceuticalRegulation

First success of selumetinib, a targeted therapy in most common NSCLC

29-11-2012

A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists…

Array BioPharmaAstraZenecaOncologyPharmaceuticalResearchselumetinib

Big Pharma doing more for access to medicine in developing countries than two years ago

28-11-2012

The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

Asthma preventive drugs market led by GlaxoSmithKline's Advair

26-11-2012

The asthma preventive drugs market has been forecast to increase at a compound annual growth rate (CAGR)…

AdvairAstraZenecaGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicort

AstraZeneca and Bristol-Myers get first approval for diabetes drug Forxiga

15-11-2012

There was good news for AstraZeneca (LSE: AZN) and Bristol-Myers Squibb (NYSE: BMY), with the European…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesEuropeForxigaPharmaceuticalRegulation

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Russian prostate cancer market expected to grow 6% annually from 2011 to 2016

01-11-2012

The total number of diagnosed incident cases of prostate cancer in Russia will increase at five percent…

AstraZenecaBuserelinEuropeMarkets & MarketingOncologyPharm-SintezPharmaceuticalZoladex

£7 million funding for MRC-AstraZeneca compound collaboration

30-10-2012

The UK's Medical Research Council (MRC) will today (October 31) announce £7 million ($11.3 billion)…

AstraZenecaFinancialPharmaceuticalResearch

New CEO Pascal Soriot to get over $6 million for moving to AstraZeneca

30-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has made a regulatory disclosure following the grant…

AstraZenecaFinancialManagementPharmaceutical

News briefs: Bayer's Stivarga and AstraZeneca's Faslodex

30-10-2012

German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) said yesterday…

AstraZenecaBayerFaslodexNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationResearchStivarga

AstraZeneca 3rd-qtr 2012 takes heavy hit from generics

25-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that group sales for the third…

AstraZenecaFinancialPharmaceutical

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

AstraZeneca's Brilinta rolls out in India

18-10-2012

The Indian subsidiary of Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday launched its patented…

Asia-PacificAstraZenecaBrilintaCardio-vascularMarkets & MarketingPharmaceutical

AstraZeneca partners with China's Pharmaron to accelerate drug discovery

15-10-2012

Pharmaron, a China-based R&D service provider for the pharmaceutical and biotech industries with operations…

AstraZenecaLicensingPharmaceuticalPharmaronResearch

226 to 250 of 319 results

Back to top